| Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential H Pelicano, W Zhang, J Liu, N Hammoudi, J Dai, RH Xu, L Pusztai, ... Breast cancer research 16, 1-16, 2014 | 223 | 2014 |
| Metabolic alterations in cancer cells and therapeutic implications N Hammoudi, KBR Ahmed, C Garcia-Prieto, P Huang Chinese journal of cancer 30 (8), 508, 2011 | 120 | 2011 |
| SF2312 is a natural phosphonate inhibitor of enolase PG Leonard, N Satani, D Maxwell, YH Lin, N Hammoudi, Z Peng, ... Nature chemical biology 12 (12), 1053-1058, 2016 | 87 | 2016 |
| Effective killing of leukemia cells by the natural product OSW-1 through disruption of cellular calcium homeostasis C Garcia-Prieto, KBR Ahmed, Z Chen, Y Zhou, N Hammoudi, Y Kang, ... Journal of Biological Chemistry 288 (5), 3240-3250, 2013 | 64 | 2013 |
| Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism S Yuan, Y Lu, J Yang, G Chen, S Kim, L Feng, M Ogasawara, ... Stem cell research & therapy 6, 1-15, 2015 | 54 | 2015 |
| An enolase inhibitor for the targeted treatment of ENO1-deleted cancers YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ... Nature metabolism 2 (12), 1413-1426, 2020 | 47 | 2020 |
| ENOblock does not inhibit the activity of the glycolytic enzyme enolase N Satani, YH Lin, N Hammoudi, S Raghavan, DK Georgiou, FL Muller PloS one 11 (12), e0168739, 2016 | 29 | 2016 |
| Eradication of ENO1-deleted Glioblastoma through Collateral Lethality YH Lin, N Satani, N Hammoudi, JJ Ackroyd, S Khadka, VC Yan, ... BioRxiv, 331538, 2018 | 16 | 2018 |
| The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues F Pisaneschi, YH Lin, PG Leonard, N Satani, VC Yan, N Hammoudi, ... Molecules 24 (13), 2510, 2019 | 13 | 2019 |
| Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53 MA Ogasawara, J Liu, H Pelicano, N Hammoudi, CM Croce, MJ Keating, ... Mitochondrion 31, 33-39, 2016 | 11 | 2016 |
| Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers VC Yan, CD Pham, ES Ballato, KL Yang, K Arthur, S Khadka, ... Journal of Medicinal Chemistry 65 (20), 13813-13832, 2022 | 3 | 2022 |
| Comparative pharmacology of a bis-pivaloyloxymethyl phosphonate prodrug inhibitor of enolase after oral and parenteral administration VC Yan, Y Barekatain, YH Lin, N Satani, N Hammoudi, K Arthur, ... ACS Pharmacology & Translational Science 6 (2), 245-252, 2023 | 1 | 2023 |
| Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer YH Lin, N Satani, N Hammoudi, F Pisaneschi, P Leonard, D Maxwell, ... Molecular Cancer Therapeutics 16 (10_Supplement), A39-A39, 2017 | 1 | 2017 |
| Potential role of reactive oxygen species in mediating glioblastoma stem cell differentiation F Wang, S Yuan, G Chen, S Kim, N Hammoudi, L Feng, W Lu, JS Lee, ... Cancer Research 72 (8_Supplement), 999-999, 2012 | 1 | 2012 |
| Prodrugs of a 1-hydroxy-2-oxopiperidin-3-yl phosphonate enolase inhibitor for the treatment of ENO1-deleted cancers VC Yan, CD Pham, ES Ballato, KL Yang, S Khadka, Y Barektain, ... Cancer Research 83 (7_Supplement), 3097-3097, 2023 | | 2023 |
| NAD+ biosynthesis as a collateral lethality target for precision oncology FL Muller, P Deng, YH Lin, N Satani, N Hammoudi, G Mohapatra, ... bioRxiv, 2022.12. 13.518967, 2022 | | 2022 |
| An enolase inhibitor for the targeted treatment of ENO1-deleted cancers (vol 2, pg 1413, 2020) YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ... NATURE METABOLISM 3 (1), 122-122, 2021 | | 2021 |
| Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers (Nature Metabolism,(2020), 2, 12,(1413-1426), 10.1038/s42255-020-00313-3) YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ... Nature Metabolism 3 (1), 122, 2021 | | 2021 |
| YIA19-004: Collateral Deletion of Glycolysis Genes Generates Selective Vulnerabilities to Inhibitors of Oxidative Phosphorylation F Muller, YH Lin, N Satani, N Hammoudi Journal of the National Comprehensive Cancer Network 17 (3.5), YIA19-004 …, 2019 | | 2019 |
| Collateral lethality: A new target for personalized oncology YH Lin, N Hammoudi, N Satani, J Ackroyd, S Khadka, D Georgiou, ... Cancer Research 78 (13_Supplement), 2831-2831, 2018 | | 2018 |
